Literature DB >> 2829178

Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines.

A J Linnenbach1, K Huebner, E P Reddy, M Herlyn, A H Parmiter, P C Nowell, H Koprowski.   

Abstract

A correlative study was done to determine possible relationships between nonrandom aberrations in chromosomes 1, 6, and 7 occurring in human cutaneous malignant melanoma and the structure of oncogenes as well as specific genes encoding growth factors and growth factor receptors. Thirty cell lines derived from primary or metastatic melanomas of 28 patients were analyzed by Southern blotting with nick-translated probes for 28 different genes, some of which map near frequent chromosomal breakpoints observed in melanoma. An alteration in the MYB protooncogene was observed in a cell line derived from a primary melanoma in the vertical growth phase, which correlated with a 6q22 chromosomal abnormality. Another primary melanoma cell line had a cytogenetically undetected tumor-specific deletion within the gene for alpha-type protein kinase C. Polymorphic alleles for the genes encoding the epidermal growth factor receptor and alpha-type protein kinase C were also observed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2829178      PMCID: PMC279484          DOI: 10.1073/pnas.85.1.74

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  58 in total

1.  RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination.

Authors:  H Lehrach; D Diamond; J M Wozney; H Boedtker
Journal:  Biochemistry       Date:  1977-10-18       Impact factor: 3.162

2.  Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: the architecture of a transduced oncogene.

Authors:  K H Klempnauer; T J Gonda; J M Bishop
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

3.  Chromosome 6 in malignant melanoma.

Authors:  R Becher; Z Gibas; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1983-06

4.  Chromosome 6q involvement in human malignant melanoma.

Authors:  J M Trent; S B Rosenfeld; F L Meyskens
Journal:  Cancer Genet Cytogenet       Date:  1983-06

5.  Inhibition of intractable nucleases with ribonucleoside--vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes.

Authors:  S L Berger; C S Birkenmeier
Journal:  Biochemistry       Date:  1979-11-13       Impact factor: 3.162

6.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.

Authors:  H Aviv; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

7.  Nonrandom chromosome changes in malignant melanoma.

Authors:  R Becher; Z Gibas; C Karakousis; A A Sandberg
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

8.  A t(1;19) chromosome translocation in three cases of human malignant melanoma.

Authors:  A H Parmiter; G Balaban; M Herlyn; W H Clark; P C Nowell
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

9.  Human beta-nerve growth factor gene sequence highly homologous to that of mouse.

Authors:  A Ullrich; A Gray; C Berman; T J Dull
Journal:  Nature       Date:  1983-06-30       Impact factor: 49.962

10.  Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor.

Authors:  A Gray; T J Dull; A Ullrich
Journal:  Nature       Date:  1983 Jun 23-29       Impact factor: 49.962

View more
  12 in total

1.  Isolation of human cDNA clones of myb-related genes, A-myb and B-myb.

Authors:  N Nomura; M Takahashi; M Matsui; S Ishii; T Date; S Sasamoto; R Ishizaki
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

2.  A protein kinase C cDNA without the regulatory domain is active after transfection in vivo in the absence of phorbol ester.

Authors:  M Muramatsu; K Kaibuchi; K Arai
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

3.  Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733.

Authors:  A J Linnenbach; J Wojcierowski; S A Wu; J J Pyrc; A H Ross; B Dietzschold; D Speicher; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  A single point mutation in the V3 region affects protein kinase Calpha targeting and accumulation at cell-cell contacts.

Authors:  A Vallentin; T C Lo; D Joubert
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

5.  Selective loss of substrate recognition induced by the tumour-associated D294G point mutation in protein kinase Calpha.

Authors:  C Prévostel; V Alvaro; A Vallentin; A Martin; S Jaken; D Joubert
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

6.  Biologic and therapeutic significance of MYB expression in human melanoma.

Authors:  N Hijiya; J Zhang; M Z Ratajczak; J A Kant; K DeRiel; M Herlyn; G Zon; A M Gewirtz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Involvement of the ALL-1 gene in a solid tumor.

Authors:  R Baffa; M Negrini; S A Schichman; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

Review 8.  Growth factor independence and growth regulatory pathways in human melanoma development.

Authors:  U Rodeck
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

9.  Dynamic adhesions and MARCKS in melanoma cells.

Authors:  Adriana Estrada-Bernal; Jesse C Gatlin; Somkiat Sunpaweravong; Karl H Pfenninger
Journal:  J Cell Sci       Date:  2009-06-09       Impact factor: 5.285

10.  Protein kinase C beta expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate.

Authors:  M B Powell; R K Rosenberg; M J Graham; M L Birch; D T Yamanishi; J A Buckmeier; F L Meyskens
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.